Andrew Turk, MD | Authors


Targeted Agents Evolve in Anaplastic, Medullary Thyroid Cancer Treatment Paradigms

August 28, 2019

Andrew Turk, MD, discusses targeted agents that are making a splash in the treatment landscape of thyroid cancers, including the most aggressive form of the disease, anaplastic thyroid carcinoma. He says targeted agents have already become well established in the space of thyroid cancers, but these agents continue to evolve.

Addressing the Importance of Understanding the Subtypes of Thyroid Cancer

June 27, 2019

Andrew Turk, MD, discusses the importance of discussing thyroid cancer at major meetings, such as the 2019 ASCO Annual Meeting. It is important for physicians to keep up to date on the latest advancements for treatment options and new understandings of the disease and its subtypes.